Dexamethasone IV

DRUG5 trials

Sponsors

Centre hospitalier de l'Université de Montréal (CHUM), Laval University, Sanofi, Mayo Clinic, Assistance Publique - Hôpitaux de Paris

Conditions

Arthropathy of KneeIntensive Care PediatricLung CancerPrevention of Hypersensitivity Reactions to PaclitaxelRelapsed/Refractory Multiple Myeloma

Phase 2

A Study to Investigate Subcutaneous Isatuximab in Combination With Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma

Active, not recruitingNCT05704049

SanofiRelapsed/Refractory Multiple Myeloma

Start: 2023-04-05End: 2028-05-12Updated: 2025-12-29

Phase 3

Corticosteroids Before Extubation in Pediatric Intensive Care Unit

RecruitingNCT06722118

Assistance Publique - Hôpitaux de ParisIntensive Care Pediatric

Start: 2025-10-28End: 2028-11-01Target: 348Updated: 2026-08-25

Phase 4

Randomized Study of Preoperative Dexamethasone for Quality of Recovery in VATS Lung Resection Patients

CompletedNCT02275702

Laval UniversityLung Cancer

Start: 2014-10-31End: 2016-12-31Updated: 2021-08-25

How Many Dexamethasone Doses Should Be Given Perioperatively?

Enrolling by invitationNCT06715709

Mayo ClinicArthropathy of Knee

Start: 2025-03-25End: 2027-01-01Target: 339Updated: 2026-02-06

Unknown Phase

Comparison of Two Regimens of Dexamethasone in the Prevention of Hypersensitivity Reactions to Paclitaxel, a Pilot Study

CompletedNCT01797991

Centre hospitalier de l'Université de Montréal (CHUM)Prevention of Hypersensitivity Reactions to Paclitaxel

Start: 2013-02-28End: 2013-08-31Updated: 2013-10-31

Related Papers

Safety and reliability of isatuximab subcutaneous on-body injector: Results across the phase 3 IRAKLIA, phase 2 IZALCO and phase 1b TCD15484 trials.

Journal of Clinical Oncology2026-05-28

Updated results from the phase 2 IZALCO study: Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma.

Journal of Clinical Oncology2026-05-28

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO.

2025-12-27

Home administration of isatuximab subcutaneous by on-body injector in Relapsed/Refractory multiple myeloma in the Phase 3 iraklia study

Blood2025-11-03

Efficacy and safety of isatuximab subcutaneous (SC) plus carfilzomib and dexamethasone (Isa-Kd) in patients with relapsed/refractory multiple myeloma (RRMM): Results of the phase 2 study IZALCO.

Journal of Clinical Oncology2025-05-281 citations

Effects of Steroids on Quality of Recovery and Adverse Events after General Anesthesia: Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

2016-09-1523 citations